Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
A phase 1/2 trial of EB-DART-NK01 in small-cell lung cancer, run by Beijing Biotech, now recruiting.
Overview
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC) is a phase 1/2 interventional study registered as NCT07744256 by Beijing Biotech, with 60 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-02-14. Interventions recorded: EB-DART-NK01 and Lymphodepleting chemotherapy.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialSNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer
Shares Small-cell lung cancer and the tag pipeline.
- TrialAdaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Shares Small-cell lung cancer and the tag pipeline.
- TrialPharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms
Shares Small-cell lung cancer and the tag pipeline.
- TrialA Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Shares Small-cell lung cancer and the tag pipeline.
- TrialPharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Shares Small-cell lung cancer and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Small-cell lung cancer and the tag pipeline.